Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Quality Control: SOP for Conducting Repeat Testing in QC Labs – V 2.0

Posted on By

Quality Control: SOP for Conducting Repeat Testing in QC Labs – V 2.0

Standard Operating Procedure for Conducting Repeat Testing in QC Laboratories


Department Quality Control
SOP No. SOP/QC/166/2025
Supersedes SOP/QC/166/2022
Page No. Page 1 of 13
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

This Standard Operating Procedure (SOP) outlines the proper process for conducting repeat testing in the Quality Control (QC) laboratories for sterile injectable products. The procedure ensures that any repeat analysis is scientifically justified, documented, reviewed, and approved in accordance with current Good Manufacturing

Practices (cGMP) and data integrity principles.

2. Scope

This SOP applies to all QC laboratory personnel involved in chemical, instrumental, and microbiological analysis of raw materials, in-process samples, finished products, and stability samples where test results are out-of-specification (OOS), out-of-trend (OOT), or require re-verification under specific conditions.

3. Responsibilities

  • QC Analyst: Conducts the initial and repeat tests, records all observations, and notifies any OOS/OOT findings.
  • QC Supervisor: Reviews investigation reports, assesses justification, and authorizes retesting if scientifically warranted.
  • QA Executive: Ensures compliance with SOP and verifies that the repeat testing procedure was correctly followed.
  • Head QC: Provides final approval for repeat testing and oversees completion of investigation and documentation.
See also  Sterile Injectable Manufacturing: SOP for Assay Testing of Active Ingredients in Injections - V 2.0

4. Accountability

The Head of Quality Control is accountable for ensuring compliance with this SOP and regulatory requirements for data integrity and repeat testing.

5. Procedure

5.1 Initial Assessment

  1. When test results fall outside of the specification or trend, the QC Analyst must immediately notify the Supervisor and QA.
  2. Initiate an Out-of-Specification (OOS) or Out-of-Trend (OOT) investigation report using Annexure-1.
  3. Conduct a preliminary laboratory investigation to check for analytical errors including:
    • Sample preparation error
    • Calculation mistakes
    • Instrument malfunction
    • Environmental influences

5.2 Conditions for Repeat Testing

Repeat testing shall be permitted only under the following conditions:

  • Confirmed analyst error in sample preparation or dilution
  • Malfunction of instrument or software (with evidence)
  • Sample contamination or spillage
  • Power failure or interruption during run
  • Results invalidated due to lab condition deviations

Repeat testing must not be used to “average out” or disregard a valid failing result unless justified with investigation and QA approval.

5.3 Approval Process for Repeat Testing

  1. Fill out the Repeat Testing Request Form (Annexure-2).
  2. Attach investigation summary with evidence and proposed corrective action.
  3. Get approval from:
    • QC Supervisor
    • QA Executive
    • Head of QC (final)
  4. Only after written authorization can repeat testing be conducted.
See also  Sterile Injectable Manufacturing: SOP for Cleaning Prefilled Syringe Filling Machines - V 2.0

5.4 Conducting Repeat Test

  1. Repeat test must follow the original method under validated conditions.
  2. Use the same batch/sample or retain if available. If not, a fresh sample can be drawn with justification.
  3. All chromatograms, graphs, printouts, and raw data must be attached to the Repeat Test Report (Annexure-3).

5.5 Documentation and Interpretation

  • All results, including initial and repeat tests, must be reported transparently.
  • Final decision must be based on investigation outcome, not solely on passing repeat test results.
  • QA shall review the repeat test data and record conclusions in the Investigation Closure Form (Annexure-4).

5.6 Reporting and Archiving

  1. All completed documents shall be filed in the batch folder.
  2. Scan and back up repeat testing reports on QC document repository.
  3. Investigation summaries must be included in Annual Product Quality Review (APQR).

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QC: Quality Control
  • QA: Quality Assurance
  • OOS: Out of Specification
  • OOT: Out of Trend
  • APQR: Annual Product Quality Review

7. Documents

  1. OOS/OOT Investigation Report – Annexure-1
  2. Repeat Testing Request Form – Annexure-2
  3. Repeat Test Report – Annexure-3
  4. Investigation Closure Form – Annexure-4
See also  Quality Control: SOP for Reviewing QC Test Results before Product Release - V 2.0

8. References

  • ICH Q2(R1) – Validation of Analytical Procedures
  • FDA Guidance on Out of Specification Results (October 2006)
  • WHO TRS No. 996 – GMP for QC Labs

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QC Analyst QA Executive Head QC
Department Quality Control Quality Assurance Quality Control

11. Annexures

Annexure-1: OOS/OOT Investigation Report

Batch No. Sample Type Test Performed OOS/OOT Observed Initial Analyst
INJ-B120 Finished Product Assay OOS – Low Result Meena R.

Annexure-2: Repeat Testing Request Form

Date Reason for Repeat Justification Requested By
22/06/2025 Instrument Fluctuation Power interruption mid-run Meena R.

Annexure-3: Repeat Test Report

Test Initial Result Repeat Result Analyst Remarks
Assay 92.4% 98.1% Ravi Jha Accepted

Annexure-4: Investigation Closure Form

Investigation ID Conclusion Corrective Action QA Reviewer
INV-0254 Power failure confirmed UPS backup enhancement Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
05/01/2022 1.0 Initial Issue Procedure Introduction Head QC
24/06/2025 2.0 Revised annexures, added instrument error cases Annual SOP Review Head QC
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Gel Manufacturing: SOP for Process Validation of Gel Manufacturing Batches – V 2.0
Next Post: No Documented SOP Assessment Post Regulatory Updates: A Major GMP Oversight

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version